Title | Author(s) | Issue date | ???itemlist.??? |
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton | Mountzios, G.; Dimopoulos, M. A.; Bamias, A.; Papadopoulos, G.; Kastritis, E.; Syrigos, K.; Pavlakis, G.; Terpos, E. | 24-Nov-2015 | - |
Antitumour and toxic effects on Wistar rats of two new platinum complexes | Charalabopoulos, K.; Karkabounas, S.; Ioachim, E.; Papalimneou, V.; Syrigos, K.; Evangelou, A.; Agnantis, N.; Hadjiliadis, N. | 24-Nov-2015 | - |
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group | Pectasides, D.; Samantas, E.; Fountzilas, G.; Briasoulis, E.; Kosmidis, P.; Skarlos, D.; Dimopoulos, M. A.; Kalofonos, H. P.; Economopoulos, T.; Syrigos, K. | 24-Nov-2015 | - |
Correlation of E-cadherin expression with clinicopathological data in patients suffering from transitional cell carcinoma of the bladder | Charalabopoulos, K.; Tsambalas, S.; Syrigos, K.; Giannakopoulos, X.; Kalfakakou, V.; Kiortsis, D.; Alamanos, J.; Charalabopoulos, A.; Evangelou, A.; Sofikitis, N.; Agnantis, N. J. | 24-Nov-2015 | - |
Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study | Bamias, A.; Syrigos, K.; Fountzilas, G.; Tzamakou, E.; Soulti, K.; Karavasilis, V.; Alamanos, Y.; Christodoulou, C.; Pavlidis, N. | 24-Nov-2015 | - |
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid | Mountzios, G.; Terpos, E.; Syrigos, K.; Papadimitriou, C.; Papadopoulos, G.; Bamias, A.; Mavrikakis, M.; Dimopoulos, M. A. | 24-Nov-2015 | - |
Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data | Mauri, D.; Pentheroudakis, G.; Bafaloukos, D.; Pectasides, D.; Samantas, E.; Efstathiou, E.; Kalofonos, H. P.; Syrigos, K.; Klouvas, G.; Papakostas, P.; Kosmidis, P.; Fountzilas, G.; Pavlidis, N. | 24-Nov-2015 | - |
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, A.; Maniadakis, N.; Aravantinos, G.; Syrigos, K.; Bamias, A.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G.; Bafaloukos, D.; Pavlidis, N.; Daniilidis, J. | 24-Nov-2015 | - |
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors | Pentheroudakis, G.; Fountzilas, G.; Kalofonos, H. P.; Golfinopoulos, V.; Aravantinos, G.; Bafaloukos, D.; Papakostas, P.; Pectasides, D.; Christodoulou, C.; Syrigos, K.; Economopoulos, T.; Pavlidis, N. | 24-Nov-2015 | - |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer | Bamias, A.; Papamichael, D.; Syrigos, K.; Pavlidis, N. | 24-Nov-2015 | - |
Second line chemotherapy with irinotecan (CPT-11) and mitomycin-C (MMC) in patients with advanced/metastatic colorectal (CC) and gastric cancer (GC): A phase II trial | Papamichael, D.; Bamias, A.; Ioannides, G.; Syrigos, K.; Demosthenous, C.; Pavlidis, N. | 24-Nov-2015 | - |
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2 | Kosmidis, P. A.; Syrigos, K.; Kalofonos, H. P.; Dimopoulos, M. A.; Skarlos, D.; Pavlidis, N.; Boukovinas, I.; Bafaloukos, D.; Pectasides, D.; Bacoyiannis, C.; Fountzilas, G. | 24-Nov-2015 | - |